In honor of National Depression Education and Awareness Month, Mallory speaks with Dr. Scott Fisher, lead psychiatrist and facilitator at the Center for Psychedelic and Cannabis Research for October’s Spotlight Podcast.
Kicking off with a brief overview of the complexities of depression and available treatments, Dr. Fisher then goes into detail on his area of expertise: research into psilocybin-facilitated and MDMA-facilitated psychotherapy as novel tools for treating depression, anxiety, PTSD, and other disorders.
With the exponential increase in interest in psychedelics, Dr. Fisher explains the importance of the patient’s mindset and the actual setting (‘set and setting’) on the efficacy of the therapeutic as well as on the patient’s positive experience when leading the psychedelic dosing sessions. Finally, he talks about what is involved in conducting psychedelic studies — from establishing appropriate dosing room settings, to the added regulatory considerations, to the psychedelic therapeutic expertise of the primary and support staff at the site.
We recognize that mental health clinical research is a particularly challenging area within research so we’ve brought together stakeholders from pharma, CRO’s, and sites to identify some obstacles and challenges unique to CNS research.
WHY GET STARR CERTIFIED?
The Messaging Committee created a series of commercials to address the stigma of mental illness and promote research. These videos are available to Coalition members to use for website, social media, or television spots. We can edit your organizations information to the end of the spots. To see more videos, log into the Community Login and look in the Gallery.
A Thank You Letter to the Women who Raised Researchers… By Molly Little, Community Outreach Director for Neuro-Behavioral Research & the Ohio Center for Hope Growing up in middle America […]